Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $117.26 million. The enterprise value is $164.77 million.
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 277.66 million shares outstanding. The number of shares has increased by 9.89% in one year.
| Current Share Class | 277.66M |
| Shares Outstanding | 277.66M |
| Shares Change (YoY) | +9.89% |
| Shares Change (QoQ) | +2.69% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 41.34% |
| Float | 272.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.59 |
| Forward PS | 1.16 |
| PB Ratio | 5.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.46 |
| P/OCF Ratio | 7.43 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 11.89 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 10.15.
| Current Ratio | 1.36 |
| Quick Ratio | 1.21 |
| Debt / Equity | 10.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | 14.92 |
| Interest Coverage | -1.28 |
Financial Efficiency
Return on equity (ROE) is -143.83% and return on invested capital (ROIC) is -5.37%.
| Return on Equity (ROE) | -143.83% |
| Return on Assets (ROA) | -3.56% |
| Return on Invested Capital (ROIC) | -5.37% |
| Return on Capital Employed (ROCE) | -11.18% |
| Weighted Average Cost of Capital (WACC) | 5.82% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | -$229,691 |
| Employee Count | 194 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, AKBA has paid $1.38 million in taxes.
| Income Tax | 1.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.41% in the last 52 weeks. The beta is 0.23, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -74.41% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 34.92 |
| Average Volume (20 Days) | 7,466,796 |
Short Selling Information
The latest short interest is 27.20 million, so 9.80% of the outstanding shares have been sold short.
| Short Interest | 27.20M |
| Short Previous Month | 23.07M |
| Short % of Shares Out | 9.80% |
| Short % of Float | 9.97% |
| Short Ratio (days to cover) | 3.17 |
Income Statement
In the last 12 months, AKBA had revenue of $197.20 million and -$44.56 million in losses. Loss per share was -$0.17.
| Revenue | 197.20M |
| Gross Profit | 159.83M |
| Operating Income | -20.09M |
| Pretax Income | -43.18M |
| Net Income | -44.56M |
| EBITDA | -18.76M |
| EBIT | -20.09M |
| Loss Per Share | -$0.17 |
Full Income Statement Balance Sheet
The company has $159.25 million in cash and $206.77 million in debt, with a net cash position of -$47.52 million or -$0.17 per share.
| Cash & Cash Equivalents | 159.25M |
| Total Debt | 206.77M |
| Net Cash | -47.52M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 20.37M |
| Book Value Per Share | 0.07 |
| Working Capital | 58.44M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $15.78 million and capital expenditures -$1.92 million, giving a free cash flow of $13.86 million.
| Operating Cash Flow | 15.78M |
| Capital Expenditures | -1.92M |
| Depreciation & Amortization | 1.34M |
| Net Borrowing | -19.58M |
| Free Cash Flow | 13.86M |
| FCF Per Share | $0.05 |
Full Cash Flow Statement Margins
Gross margin is 81.05%, with operating and profit margins of -10.19% and -22.60%.
| Gross Margin | 81.05% |
| Operating Margin | -10.19% |
| Pretax Margin | -21.90% |
| Profit Margin | -22.60% |
| EBITDA Margin | -9.51% |
| EBIT Margin | -10.19% |
| FCF Margin | 7.03% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.89% |
| Shareholder Yield | -9.89% |
| Earnings Yield | -40.18% |
| FCF Yield | 11.82% |
Analyst Forecast
The average price target for AKBA is $2.67, which is 531.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.67 |
| Price Target Difference | 531.54% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -22.99% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -5.72 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.72 |
| Piotroski F-Score | 3 |